索拉非尼联合经皮肝动脉化疗栓塞术治疗肝细胞癌的Meta分析

杨君; 孟庆华; 于红卫

doi:10.3969/j.issn.1001-5256.2013.10.011

索拉非尼联合经皮肝动脉化疗栓塞术治疗肝细胞癌的Meta分析

DOI: 10.3969/j.issn.1001-5256.2013.10.011

1. 首都医科大学附属北京佑安医院肿瘤微创介入中心
2. 首都医科大学附属北京佑安医院重肝科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2910
- HTML全文浏览量: 11
- PDF下载量: 642
- 被引次数: 0
出版历程
- 收稿日期: 2012-11-26
- 出版日期: 2013-10-20

Sorafenib combined with thanscatheter artierial chemoembolzation in treatment of advanced hepatocellular carcinoma: Meta analysis

Oncology Minimally Invasive Intervention Center, Beijing You'an Hospital, Capital Medical University

摘要

摘要:
目的系统评价索拉非尼联合经皮肝动脉化疗栓塞术（TACE）治疗晚期肝细胞癌的疗效与安全性。方法计算机检索PubMed（1966年-2012年9月）、Embase（1990年-2012年9月）、中国期刊全文数据库（1994年-2012年9月）、中国生物医学文献数据库（1978年-2012年9月）、中文科技期刊数据库（1989年-2012年9月）、中华医学会数字化期刊库（1997年-2012年9月）,同时手检相关期刊和会议论文集,纳入有关索拉非尼治疗晚期肝细胞癌的随机对照试验,按Cochrane系统评价方法提取资料、评价文献质量并进行统计学分析,数据采用RevMan 5.0软件进行分析。结果最终纳入7个随机对照试验,共854例患者。与索拉非尼组相比,索拉非尼联合TACE组能够延长肝癌患者的总生存期,但是不能降低病死率,手足反应、腹泻、皮疹、高血压的发生率增加,脱发的发生率没有差异。结论索拉非尼联合TACE治疗晚期肝细胞癌有效而安全。
- 索拉非尼 /
- 肝肿瘤 /
- 化学栓塞,治疗性 /
- Meta分析
Abstract:
Objective To evaluate the effectiveness and toxicities of sorafenib combined with thanscatheter artierial chemoembolzation ( TACE) in the treatment of advanced hepatocellular carcinoma ( HCC) . Methods According to the Cochrane handbook for systematic review, two reviewers independently completed the whole process of literature search, study selection, data collection, and quality assessment. A manual and computerized search was performed using the PubMed, Embase, Chinese Journal Full- text Database, Chinese Biomedical Literature Database, VIP Database for Chinese Technical Periodicals, and Chinese Medical Association Digital Periodicals to collect randomized controlled trials ( RCT) of sorafenib in the treatment of advanced HCC published up to September 2012. The obtained data were analyzed with RevMan 5. 0 software. Results Seven RCT involving 854 patients were finally included. Compared with sorafenib alone, sorafenib combined with TACE significantly prolonged the overall survival in HCC patients, but failed to reduce their mortality. The incidence of hand- foot syndrome, diarrhea, rash, and hypertension was significantly higher in combined treatment groups than in control groups, but the incidence of alopecia showed no significant difference between them. Conclusion Sorafenib combined with TACE are effective and safe in the treatment of advanced HCC.
- sorafenib /
- liver neoplasms /
- chemoembolization, therapeutic /
- Meta analysis

HTML全文

参考文献(18)

[1]SUN JJ, ZHAO HJ, LI W, et al.Clinical study of radiofrequency ablation therapy in combination with sorafenib for advanced hepatocellular carcinoma[J].J Clin Hepatol, 2011, 27 (10) :1093-1095. (in Chinese) 孙景娟, 赵恒军, 李薇, 等.射频消融联合索拉非尼治疗进展期肝细胞癌的临床观察[J].临床肝胆病杂志, 2011, 27 (10) :1093-1095.

[2]CHEN MS, LIU FR.The role of radiofrequency ablation in multidisciplinary treatment of hepatocellular carcinoma[J].J Clin Hepatol, 2011, 27 (4) :368-371. (in Chinese) 陈敏山, 刘芙蓉.射频消融在肝癌多学科综合治疗中的应用[J].临床肝胆病杂志, 2011, 27 (4) :368-371.

[3]HAN GH, BAI W, LIANG J, et al.Clinical study of TACE combined sorafenib on advanced hepatocellular carcinoma[J].Chin Clin Oncol, 2009, 14 (5) :401-404. (in Chinese) 韩国宏, 白苇, 梁洁, 等.TACE联合索拉非尼治疗中晚期肝细胞肝癌的初步观察[J].临床肿瘤学杂志, 2009, 14 (5) :401-404.

[4]WILHELM SM, CARTER C, TANG L, et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res, 2004, 64 (19) :7099-7109.

[5]ZHANG X, YANG XR, HUANG XW, et al.Sorafenib in treatment of patients with advanced hepatocellular carcinoma:a systematic review[J].Hepatobiliary Pancreat Dis Int, 2012, 11 (5) :458-466.

[6]Chinese Society of Liver Cancer;Chinese Society of Clinical Oncology;Liver Cancer Group, Chinese Society of Hepatology.Consensus on standardized diagnosis and treatment of primary liver cancer[J].J Clin Hepatol, 2009, 25 (2) :83-92. (in Chinese) 中国抗癌协会肝癌专业委员会;中国抗癌协会临床肿瘤学协作专业委员会;中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识[J].临床肝胆病杂志, 2009, 25 (2) :83-92.

[7]JADAD AR, MOORE A, CARROLL D, et al.Assessing the quality of reports of randomized clinical trials:Is blinding necessary?[J].Control Clin Trials, 1996, 17 (1) :1-12.

[8]SIEGHART W, PINTER M, REISEGGER M, et al.Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma:a pilot study[J].Eur Radiol, 2012, 22 (6) :1214-1223.

[9]WEI ZG, LU LG, SHAO PJ, et al.Clinical observation of transcatheter arterial chemoembolization combined with sorafenib on intermediate-advanced hepatocellular carcinoma[J].Chin J Radiol, 2012, 46 (3) :252-256. (in Chinese) 魏照光, 陆骊工, 邵培坚, 等.肝动脉化疗栓塞联合索拉非尼治疗中晚期肝细胞癌的临床疗效观察[J].中华放射学杂志, 2012, 46 (3) :252-256.

[10]YU JW, ZHANG LH.Therapeutic efficacy of TACE combined with molecular targeted agent therapy in treatment of hepato cellular carcinoma[J].Chin Pract Med, 2011, 6 (31) :180-181. (in Chinese) 于建伟, 张丽红.TACE联合分子靶向药物治疗肝细胞癌的疗效观察[J].中国实用医药, 2011, 6 (31) :180-181.

[11]JIANG HY, XIE XD.Sorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma[J].Hainan Med J, 2010, 21 (23) :6-9. (in Chinese) 姜海英, 谢晓东.索拉非尼联合TACE术治疗中晚期肝细胞癌30例临床观察[J].海南医学, 2010, 21 (23) :6-9.

[12]WU XB, LIN DX, ZHOU MT, et al.Clinical effect of transcatheter arterial chemoembolization combined with Sorafenib on advanced hepatocellular carcinoma[J].J Hepatopancreatobiliary Surg, 2010, 22 (6) :466-468. (in Chinese) 吴祥斌, 林德新, 周蒙滔, 等.TACE联合索拉非尼治疗中晚期肝癌疗效观察[J].肝胆胰外科杂志, 2010, 22 (6) :466-468.

[13]WEI XY, RAO RS.Sorafenib Combination with Transcatheter Arterial Chemoembolization for Treatment of Advanced Hepatocellular Carcinoma[J].Pract Clin Med, 2009, 10 (11) :17-19. (in Chinese) 魏小勇, 饶荣生.索拉非尼联合TACE治疗中晚期肝癌的临床观察[J].实用临床医学, 2009, 10 (11) :17-19.

[14] HAN GH.Progress in chinical research on combination therapy with sorafenib[N].Hepatology Digest, 2012, 66:10-11. (in Chinese) 韩国宏.索拉非尼联合治疗的临床研究进展[N].国际肝病, 2012, 66:10-11.

[15]KUDO M, IMANAKA K, CHIDA N, et al.Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J].Eur J Cancer, 2011, 47 (14) :2117-2127.

[16]LLOVET JM, RICCI S.Sorafenib in advanced hepatocellular carcinoma[J].New Engl J Med, 2008, 359 (4) :378-390.

[17]REYES DK, VOSSEN JA, KAMEL IR, et al.Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma:initial experience in the United States[J].Cancer J, 2009, 15 (6) :526-532.

[18]TIMOTHY M.PAWLIK, DIANE K.Reyes, David Cosgrove, et al.Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma[J].J Clin Oncol, 2011, 29 (30) :3960-3967.

施引文献

资源附件(0)

访问统计